Proton Pump Inhibitor Empirical Treatment in Management of Outpatients with Gastroesophageal Reflux Disease.

Exclusion Criteria

• ○ If participating in any interventional clinical trial.
• ○ Patient with alarm symptom of oncology(weight loss, recurrent dysphagia, anemia, hematemesis, melena).
• ○ Continuous application of nonsteroidal anti-inflammation drugs or acid suppressive drug within 2 weeks before screening.
• ○ The need for H2-receptor antagonists (H2RA) including cimetidine, ranitidine and famotidine or sucralfate, antacids, traditional Chinese medicine and prokinetics during the upcoming 4 weeks (study duration).
• ○ Previous gastroesophageal surgery.
• ○ Upper gastrointestinal malignancy, achalasia, and esophageal spasm or stricture.
• ○ Peptic ulcer
• ○ Diabetes
• ○ Cerebral vascular disease
• ○ Zollinger-Ellison syndrome
• ○ Scleroderma
• ○ Hiatus hernia women
• ○ Pregnant or lactating women
• ○ Any other subjects were not suitable to this study in the opinion of the investigator.